Differential effects of inactivated Axin1 and activated β-catenin mutations in human hepatocellular carcinomas
Open accessAbstract
Perturbations to the Wnt signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs). Activating beta-catenin mutations and loss of function mutations in Axin1 are thought to be functionally equivalent. We examined the Wnt pathway in HCC by comparing the expression of beta-catenin target genes and the level of beta-catenin-dependent transcriptional activation, in 45 HCC tumors and four cell lines. Among these samples, beta-catenin and AXIN1 were mutated in 20 and seven cases, respectively. We found a significant correlation between activated beta-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR)49 and glutamate transporter (GLT)-1 (P=0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1. We also showed that GS is a good immunohistochemical marker of beta-catenin activation in HCC. However, we observed no induction of GS, GPR49 or GLT-1 in the five inactivated Axin1 tumors. Beta-catenin-dependent transcriptional activation in two Axin1-mutated HCC cell lines was much weaker than in beta-catenin-mutated cell lines. Our results strongly suggest that in HCC, contrary to expectation, the loss of function of Axin1 is not equivalent to the gain of function of beta-catenin. Our results also suggest that the tumor suppressor function of Axin1 in HCC may be related to another, non-Wnt pathway.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In CTNNB1-class, 7 out of 9 reported liver-related Wnt-target-genes (GLUL, REG3A, LGR5, MERTK, TBX3, EPHB2 and SPARCL1) were significantly up-regulated.
“In CTNNB1-class, 7 out of 9 reported liver-related Wnt-target-genes (GLUL, REG3A, LGR5, MERTK, TBX3, EPHB2 and SPARCL1) (26) were significantly up-regulated”
From Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib (2012) · cites this paper as [26]
Cited by
Sorted by citations
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218 · see citing works
“Around one third of HCCs have activation of the Wnt signaling pathway (particularly HCVrelated HCCs), as a result of activating mutations in the transcription factor ß-catenin [175,317,318], overexpression of Frizzled receptors or inactivation of E-cadherin or members of the degradation complex (GSK3B, AXIN, adenomato…”
BackgroundSignaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773 · see citing works
Mutations and mechanisms of WNT pathway tumour suppressors in cancer
Bugter, J. M., Fenderico, N., & Maurice, M. M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00307-z · Cited by 466 · see citing works
Lachenmayer, A., Alsinet, C., Savic, R., Cabellos, L., Toffanin, S., Hoshida, Y., Villanueva, A., Minguez, B., Newell, P., Tsai, H.-W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2322 · Cited by 306 · see citing works
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Montironi, C., Castet, F., Haber, P. K., Pinyol, R., Torres-Martin, M., Torrens, L., Mesropian, A., Wang, H., Puigvehi, M., Maeda, M., et al. (2023) · Gut · doi:10.1136/gutjnl-2021-325918 · Cited by 253 · see citing works
Cholestasis is a marker for hepatocellular carcinomas displaying β‐<i>catenin</i> mutations
Audard, V, Grimber, G., Elie, C., Radenen, B., Audebourg, A., Letourneur, F., Soubrane, O., Vacher‐Lavenu, M., Perret, C., Cavard, C., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2169 · Cited by 162 · see citing works
Self-citationHale, G., Liu, X., Hu, J., Xu, Z., Che, L., Solomon, D., Tsokos, C., Shafizadeh, N., Chen, X., Gill, R., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.122 · Cited by 73 · see citing works
- Authors
- Zucman-Rossi, J., Benhamouche, S., Godard, C., Boyault, S., Grimber, G., Balabaud, C., Cunha, A. S., Bioulac-Sage, P., & Perret, C.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Corresponding author
- Perret, C
- Venue
- Oncogene
- Published
- 2006-09-11
- Volume
- 26
- Issue
- 5
- Pages
- 774-780
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1969649798
- Cited by
- 256
- References
- 0
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 10 · 2023: 6 · 2022: 10 · 2021: 17 · 2020: 13 · 2019: 13 · 2018: 15 · 2017: 15 · 2016: 20 · 2015: 19 · 2014: 14 · 2013: 18 · 2012: 20
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Oncogene (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Keywords
- hepatocellular carcinoma, Wnt signaling, CTNNB1 mutation, glutamine synthetase, GLT-1, tumor suppressor function, immunohistochemical markers
- MeSH terms
- Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Mutation, Repressor Proteins, Tumor Cells, Cultured, beta Catenin, Axin Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review